On August 14, 2023, Bob Myers, the Chief Financial Officer of Predictive Oncology Inc. (Company), notified the company of his intent to resign from the company effective September 30, 2023 (Transition Date). Mr. Myers has also served as the Company's principal financial and principal accounting officer. On August 16, 2023, the company entered into a consulting agreement (the ?Consulting Agreement?) with Danforth Advisors, LLC (?Danforth?), pursuant to which Danforth will provide to the Company certain finance, accounting and administrative services, including that of interim chief financial officer.

As such, Josh Blacher of Danforth, an experienced biotech executive who specializes in strategic finance and corporate development, has been named as the Company?s Interim Chief Financial Officer. Prior to the Transition Date, Mr. Blacher will serve as a consultant to the Company pursuant to the Consulting Agreement. After the Transition Date, Mr. Blacher will also serve as the Company's principal financial officer and principal accounting officer.

Mr. Blacher has served as a consultant with Danforth since September 2022 and as Managing Partner of Columbus Circle Capital LLC (?Columbus Circle Capital?) since August 2019. During his tenure at Columbus Circle Capital, Mr. Blacher has served as CFO at several public and private companies. Prior to his tenure at Columbus Circle Capital, Mr. Blacher served as Chief Business Officer at Inmed Pharmaceuticals from April 2018 to August 2019, as Chief Financial Officer of Therapix Biosciences from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals from October 2014 to March 2017.

Mr. Blacher holds a Bachelor of Arts from Yeshiva University and a Master of Business Administration from Columbia Business School.